TY - JOUR
T1 - The Interferons
T2 - Mechanisms of Action and Clinical Applications
AU - Baron, Samuel
AU - Tyring, Stephen K.
AU - Fleischmann, W. Robert
AU - Coppenhaver, Dorian H.
AU - Niesel, David W.
AU - Klimpel, Gary R.
AU - Stanton, G. John
AU - Hughes, Thomas K.
PY - 1991/9/11
Y1 - 1991/9/11
N2 - The interferons (IFN) are one of the body’s natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (α, β, and γ), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi’s sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs α and β and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.
AB - The interferons (IFN) are one of the body’s natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (α, β, and γ), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi’s sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs α and β and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.
UR - http://www.scopus.com/inward/record.url?scp=0025766427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025766427&partnerID=8YFLogxK
U2 - 10.1001/jama.266.10.1375
DO - 10.1001/jama.266.10.1375
M3 - Article
C2 - 1715409
AN - SCOPUS:0025766427
SN - 0098-7484
VL - 266
SP - 1375
EP - 1383
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 10
ER -